Startups alumni
© Adobe Stock
Since the first spin-off set up in 1997, many companies have launched their business at the Institut Pasteur and generally maintain ties with the Institute.
Testimony
Eligo Bioscience is a next-generation microbiome precision medicine company. Eligo Bioscience is pioneering the development of phage-derived DNA delivery vectors for microbial species involved in a number of disease areas, including infectious diseases, inflammatory diseases and auto-immune diseases.
Eligo Bioscience was set up in 2014 based on research from the Lu Lab (MIT, USA) and the Marraffini Lab (Rockefeller University, USA). Eligo was incubated at the Institut Pasteur in Paris from 2014 to 2017 and moved to the “Paris Biotech Santé” biotech cluster at Cochin Hospital in 2017.
David Bikard, Co-founder and CSO of Eligo Bioscience, is Head of the Synthetic Biology Lab at the Institut Pasteur.
David Bikard, Co-founder and CSO of Eligo Bioscience, is Head of the Synthetic Biology Lab at the Institut Pasteur.
Xavier Duportet, Co-founder and CEO of Eligo Bioscience
Our continued collaboration with the Institut Pasteur creates a continuous link between basic research and real-life applications, while providing access to important biological resources and cutting edge-technologies. This fluid interaction is critical to our progress.
